GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Notes Receivable

MBX (MBX Biosciences) Notes Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences Notes Receivable?

MBX Biosciences's Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


MBX Biosciences Notes Receivable Historical Data

The historical data trend for MBX Biosciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences Notes Receivable Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24
Notes Receivable
- - -

MBX Biosciences Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial - - - - -

MBX Biosciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


MBX Biosciences Notes Receivable Related Terms

Thank you for viewing the detailed overview of MBX Biosciences's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


MBX Biosciences Business Description

Traded in Other Exchanges
N/A
Address
11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.